Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Capital Expenditures (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Capital Expenditures for 6 consecutive years, with -$606000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 227.57% to -$606000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $421000.0 through Sep 2025, down 86.51% year-over-year, with the annual reading at $509000.0 for FY2024, 81.63% down from the prior year.
  • Capital Expenditures for Q4 2025 was -$606000.0 at 4D Molecular Therapeutics, down from -$91000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $6.4 million in Q1 2022, with the low at -$8.2 million in Q3 2022.
  • Average Capital Expenditures over 5 years is $320800.0, with a median of $353000.0 recorded in 2023.
  • The sharpest move saw Capital Expenditures plummeted 471.93% in 2021, then soared 4322.76% in 2022.
  • Over 5 years, Capital Expenditures stood at -$1.8 million in 2021, then soared by 135.26% to $640000.0 in 2022, then soared by 279.06% to $2.4 million in 2023, then crashed by 107.63% to -$185000.0 in 2024, then crashed by 227.57% to -$606000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at -$606000.0, -$91000.0, and $557000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.